Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31623958 | 0.87 | LMNA (0.32) | LMNANPSR1TSHRHSD17B10MEN1 | |
| SCHEMBL22581341 | 0.85 | LMNA (0.32) | LMNANPSR1TSHRHSD17B10MEN1 | |
| SCHEMBL31451893 | 0.83 | NPSR1 (0.35) | LMNANPSR1MEN1KMT2A | |
| SCHEMBL29525162 | 0.80 | — | — | |
| SCHEMBL31624088 | 0.78 | LMNA (0.32) | LMNANPSR1TSHRHSD17B10MEN1 | |
| SCHEMBL9154034 | 0.78 | NPSR1 (0.41) | LMNANPSR1TSHRHSD17B10MEN1 | |
| SCHEMBL5084605 | 0.78 | NPSR1 (0.41) | LMNANPSR1TSHRHSD17B10MEN1 | |
| SCHEMBL31623852 | 0.76 | LMNA (0.33) | LMNANPSR1 | |
| SCHEMBL27171061 | 0.75 | NPSR1 (0.35) | LMNANPSR1TSHRHSD17B10MEN1 | |
| Trifluoroacetic Acid SCHEMBL23358807 | 0.74 | MEN1 (0.32) | LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224262-A1 | COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025224249-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025090727-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2022098970-A9 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-4143184-A1 | COMPOUNDS USEFUL FOR INHIBITING RET KINASE | Eli Lilly and Company (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022098970-A1 | PYRAZOLE DERIVATIVES ASR ET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-05-12 | — | — | WO | disclosed |